PL2299987T3 - Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu - Google Patents
Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonuInfo
- Publication number
- PL2299987T3 PL2299987T3 PL09757593T PL09757593T PL2299987T3 PL 2299987 T3 PL2299987 T3 PL 2299987T3 PL 09757593 T PL09757593 T PL 09757593T PL 09757593 T PL09757593 T PL 09757593T PL 2299987 T3 PL2299987 T3 PL 2299987T3
- Authority
- PL
- Poland
- Prior art keywords
- dosage form
- pharmaceutical dosage
- suspension formulation
- capsule pharmaceutical
- indolinone derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157748 | 2008-06-06 | ||
| EP09757593.0A EP2299987B1 (en) | 2008-06-06 | 2009-06-04 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
| PCT/EP2009/056878 WO2009147212A1 (en) | 2008-06-06 | 2009-06-04 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2299987T3 true PL2299987T3 (pl) | 2018-08-31 |
Family
ID=40911908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09757593T PL2299987T3 (pl) | 2008-06-06 | 2009-06-04 | Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US20110301177A1 (pl) |
| EP (1) | EP2299987B1 (pl) |
| JP (2) | JP5661031B2 (pl) |
| KR (2) | KR20170020557A (pl) |
| CN (2) | CN102056598B (pl) |
| AR (1) | AR072059A1 (pl) |
| AU (1) | AU2009254548B2 (pl) |
| BR (1) | BRPI0913434B8 (pl) |
| CA (1) | CA2726267C (pl) |
| CL (1) | CL2010001279A1 (pl) |
| CO (1) | CO6280467A2 (pl) |
| CY (1) | CY1120533T1 (pl) |
| DK (1) | DK2299987T3 (pl) |
| EA (1) | EA029996B1 (pl) |
| EC (1) | ECSP10010660A (pl) |
| ES (1) | ES2669469T3 (pl) |
| HR (1) | HRP20180709T1 (pl) |
| HU (1) | HUE039187T2 (pl) |
| IL (1) | IL208954A (pl) |
| LT (1) | LT2299987T (pl) |
| MA (1) | MA32385B1 (pl) |
| MX (2) | MX2010013203A (pl) |
| MY (1) | MY158930A (pl) |
| NO (1) | NO2299987T3 (pl) |
| NZ (1) | NZ603162A (pl) |
| PE (1) | PE20100254A1 (pl) |
| PL (1) | PL2299987T3 (pl) |
| PT (1) | PT2299987T (pl) |
| RS (1) | RS57142B1 (pl) |
| SI (1) | SI2299987T1 (pl) |
| TW (1) | TW201002691A (pl) |
| UA (1) | UA104590C2 (pl) |
| UY (1) | UY31879A (pl) |
| WO (1) | WO2009147212A1 (pl) |
| ZA (1) | ZA201007636B (pl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| MX2010013203A (es) | 2008-06-06 | 2011-02-25 | Boehringer Ingelheim Int | Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona. |
| JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| US20130202693A1 (en) * | 2010-06-02 | 2013-08-08 | Astellas Deutschland Gmbh | Oral Dosage Forms of Bendamustine |
| GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| JP2015532272A (ja) | 2012-09-28 | 2015-11-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ |
| US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
| JP6799201B2 (ja) | 2013-07-31 | 2020-12-16 | アヴァリン ファーマ インク． | エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 |
| US20150209360A1 (en) * | 2014-01-30 | 2015-07-30 | Orbz, Llc | Oral caffeine delivery composition |
| CN106031716B (zh) * | 2015-03-13 | 2022-04-15 | 江苏豪森药业集团有限公司 | 含有吲哚满酮衍生物混悬液的药物制剂及其制备方法 |
| KR102643821B1 (ko) | 2015-06-06 | 2024-03-07 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
| CN107019697A (zh) * | 2016-02-02 | 2017-08-08 | 瑞阳(苏州)生物科技有限公司 | 预防或治疗纤维化疾病的药物组合物及其应用 |
| KR102657707B1 (ko) | 2016-06-02 | 2024-04-15 | 에이디에스 테라퓨틱스 엘엘씨 | 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법 |
| US10561630B2 (en) * | 2016-10-25 | 2020-02-18 | Glykon Technologies Group, Llc | Hydroxycitric acid compounds and capsule liquid delivery |
| CN108066343A (zh) * | 2016-11-08 | 2018-05-25 | 瑞阳(苏州)生物科技有限公司 | 一种预防或治疗肾纤维化疾病的药物 |
| WO2018108669A1 (en) | 2016-12-12 | 2018-06-21 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol |
| EP3600322A1 (en) | 2017-03-28 | 2020-02-05 | Boehringer Ingelheim International GmbH | Nintedanib for use in methods for the treatment of muscular dystrophy |
| CN107184549B (zh) * | 2017-04-11 | 2020-11-20 | 江苏大学 | 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法 |
| ES3041129T3 (en) | 2017-10-23 | 2025-11-07 | Boehringer Ingelheim Int | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) |
| WO2019106692A1 (en) * | 2017-11-29 | 2019-06-06 | Sun Pharmaceutical Industries Limited | Oral suspension of nintedanib esylate |
| PL3761980T3 (pl) | 2018-03-07 | 2024-06-10 | Pliant Therapeutics, Inc. | Związki aminokwasowe i sposoby zastosowania |
| CN113292537B (zh) | 2018-06-15 | 2024-04-05 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| CN113301884A (zh) * | 2018-09-13 | 2021-08-24 | 夫特弗制药私人有限公司 | 非水性化疗口服悬浮液 |
| AU2019363244B2 (en) | 2018-10-15 | 2024-10-03 | Cipla Limited | Pharmaceutical formulation |
| CN112386580B (zh) * | 2019-08-13 | 2022-07-08 | 齐鲁制药有限公司 | 具有改善的溶出度和稳定性的尼达尼布药物制剂、制备方法及其应用 |
| KR20220109439A (ko) | 2019-12-04 | 2022-08-04 | 이도르시아 파마슈티컬스 리미티드 | 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합 |
| WO2021198253A1 (en) | 2020-04-01 | 2021-10-07 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
| EP4098246A1 (en) | 2021-05-31 | 2022-12-07 | Lotus Pharmaceutical Co., Ltd. | Formulation of nintedanib |
| CA3234791A1 (en) * | 2021-10-14 | 2023-04-20 | Eric Lefebvre | Integrin inhibitors and uses thereof in combination with other agents |
| CN114404382B (zh) * | 2022-01-24 | 2023-05-12 | 南京康川济医药科技有限公司 | 乙磺酸尼达尼布软胶囊及其制备方法 |
| CN119630395A (zh) | 2022-02-28 | 2025-03-14 | 努福米克斯技术有限公司 | 用于治疗特发性肺纤维化的组合物和方法 |
| JP2025525881A (ja) | 2022-08-16 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼内使用するためのニンテダニブの医薬製剤 |
| TW202532079A (zh) * | 2024-02-05 | 2025-08-16 | 瑩碩生技醫藥股份有限公司 | 醫藥組成物及其用途 |
| WO2025254255A1 (ko) | 2024-06-05 | 2025-12-11 | 영진약품 주식회사 | 닌테다닙 또는 이의 약학적으로 허용가능한 염을 포함하는 개선된 용출률을 갖는 신규한 정제 및 이의 제조방법 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2870062A (en) | 1956-04-27 | 1959-01-20 | Scherer Corp R P | Gelatin composition for capsules |
| GB8305693D0 (en) | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
| EP0169398B1 (de) | 1984-07-24 | 1990-08-29 | R.P. Scherer GmbH | Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung |
| GB9313329D0 (en) * | 1993-06-28 | 1993-08-11 | Scherer Ltd R P | Softgel capsule shell compositions |
| DE19603402A1 (de) | 1995-02-24 | 1996-08-29 | Basf Ag | Weichgelatinekapseln |
| US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| GEP20053654B (en) * | 2001-05-01 | 2005-11-10 | Pfizer Prod Inc | Method For Manufacturing Low Dose Pharmaceutical Composition Having Uniform Drug Distribution |
| DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US20060293260A1 (en) * | 2005-05-24 | 2006-12-28 | Wyeth | Useful high load concentrate compositions for control of ecto-and endo-parasites |
| PL1948180T3 (pl) | 2005-11-11 | 2013-09-30 | Boehringer Ingelheim Int | Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2 |
| MX2010013203A (es) | 2008-06-06 | 2011-02-25 | Boehringer Ingelheim Int | Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona. |
| PT2293795E (pt) * | 2008-06-06 | 2015-11-17 | Boehringer Ingelheim Int | Combinação farmacêutica |
| UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| JP2012515184A (ja) | 2009-01-14 | 2012-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大腸がんの治療方法 |
| US8802384B2 (en) | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| US20120142703A1 (en) | 2009-05-14 | 2012-06-07 | Boehringer Ingelheim International Gmbh | New combination therapy in treatment of oncological and fibrotic diseases |
-
2009
- 2009-06-04 MX MX2010013203A patent/MX2010013203A/es active IP Right Grant
- 2009-06-04 NZ NZ60316209A patent/NZ603162A/en unknown
- 2009-06-04 CN CN200980121067.8A patent/CN102056598B/zh not_active Ceased
- 2009-06-04 KR KR1020177004310A patent/KR20170020557A/ko not_active Withdrawn
- 2009-06-04 ES ES09757593.0T patent/ES2669469T3/es active Active
- 2009-06-04 SI SI200931833T patent/SI2299987T1/en unknown
- 2009-06-04 UA UAA201100098A patent/UA104590C2/ru unknown
- 2009-06-04 MX MX2014006908A patent/MX359229B/es unknown
- 2009-06-04 CA CA2726267A patent/CA2726267C/en active Active
- 2009-06-04 US US12/995,869 patent/US20110301177A1/en not_active Abandoned
- 2009-06-04 NO NO09757593A patent/NO2299987T3/no unknown
- 2009-06-04 EA EA201001856A patent/EA029996B1/ru not_active IP Right Cessation
- 2009-06-04 HR HRP20180709TT patent/HRP20180709T1/hr unknown
- 2009-06-04 HU HUE09757593A patent/HUE039187T2/hu unknown
- 2009-06-04 EP EP09757593.0A patent/EP2299987B1/en active Active
- 2009-06-04 PE PE2009000782A patent/PE20100254A1/es not_active Application Discontinuation
- 2009-06-04 JP JP2011512128A patent/JP5661031B2/ja active Active
- 2009-06-04 MY MYPI2010005645A patent/MY158930A/en unknown
- 2009-06-04 KR KR1020107027317A patent/KR101725469B1/ko active Active
- 2009-06-04 DK DK09757593.0T patent/DK2299987T3/en active
- 2009-06-04 PT PT97575930T patent/PT2299987T/pt unknown
- 2009-06-04 BR BRPI0913434A patent/BRPI0913434B8/pt active IP Right Grant
- 2009-06-04 WO PCT/EP2009/056878 patent/WO2009147212A1/en not_active Ceased
- 2009-06-04 RS RS20180491A patent/RS57142B1/sr unknown
- 2009-06-04 CN CN201510660732.8A patent/CN105193720B/zh not_active Ceased
- 2009-06-04 PL PL09757593T patent/PL2299987T3/pl unknown
- 2009-06-04 AU AU2009254548A patent/AU2009254548B2/en active Active
- 2009-06-04 LT LTEP09757593.0T patent/LT2299987T/lt unknown
- 2009-06-05 AR ARP090102039A patent/AR072059A1/es unknown
- 2009-06-05 TW TW098118825A patent/TW201002691A/zh unknown
- 2009-06-08 UY UY0001031879A patent/UY31879A/es not_active Application Discontinuation
-
2010
- 2010-10-26 IL IL208954A patent/IL208954A/en active IP Right Grant
- 2010-10-26 ZA ZA2010/07636A patent/ZA201007636B/en unknown
- 2010-11-22 CL CL2010001279A patent/CL2010001279A1/es unknown
- 2010-12-03 CO CO10152519A patent/CO6280467A2/es not_active Application Discontinuation
- 2010-12-03 EC EC2010010660A patent/ECSP10010660A/es unknown
- 2010-12-06 MA MA33402A patent/MA32385B1/fr unknown
-
2013
- 2013-08-30 US US14/015,186 patent/US20140004187A1/en not_active Abandoned
-
2014
- 2014-08-11 JP JP2014163667A patent/JP5905542B2/ja active Active
-
2015
- 2015-10-07 US US14/877,132 patent/US20160022672A1/en not_active Abandoned
-
2016
- 2016-07-07 US US15/204,277 patent/US9907756B2/en active Active
-
2018
- 2018-05-15 CY CY20181100499T patent/CY1120533T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201007636B (en) | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | |
| EP2429506A4 (en) | DOSAGE FOR COATED PHARMACEUTICAL CAPSULES | |
| IL209055A0 (en) | Pharmaceutical dosage form for immediate release of an indolinone derivative | |
| IL216494A (en) | A pharmaceutical dosage form containing a solid abbot-263 dispersion product | |
| GB2441053B (en) | Drug capsules for dry powder inhalers | |
| IL207128A0 (en) | Pharmaceutical dosage form | |
| IL219276A0 (en) | Gastroretentive dosage forms of poorly soluble drugs | |
| IL213545A0 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | |
| PL3766876T3 (pl) | Preparat farmaceutyczny zawierający pochodną chinolonu | |
| ZA201300241B (en) | Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof | |
| IL213546A0 (en) | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | |
| ZA201105572B (en) | Pharmaceutical composition for oral administration | |
| EP2456439A4 (en) | STABLE PHARMACEUTICAL OMEPRAZOLE FORMULATION FOR ORAL ADMINISTRATION | |
| EP2478904A4 (en) | PHARMACEUTICAL COMPOSITION FOR PERORAL ADMINISTRATION OF DIINDOLYLMETHANE | |
| EP2365812A4 (en) | PHARMACEUTICAL FORMULATIONS FOR THE IONTOPHORETIC DELIVERY OF A CORTICOSTEROID | |
| HU1000299D0 (en) | Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation | |
| HU0900482D0 (en) | Pharmaceutical formulation for oral administration | |
| HU1000444D0 (en) | Process for the preparation of a pharmaceutical active ingredient | |
| EP2404588A4 (en) | PACKAGING FOR SOLID PHARMACEUTICAL PREPARATION | |
| ITBO20070247A1 (it) | Perfezionamenti alle capsule per prodotti da infusione | |
| GB0817431D0 (en) | A capsule for oral administration | |
| GB0917118D0 (en) | A capsule for oral administration | |
| HK1141975A (en) | Paneled capsule shells for release of pharmaceutical compositions |